RWD Patients With Pulmonary Arterial Hypertension Treated With IP Prostacyclin Receptor Agonists (RAMPHA)

Hospital Costa del Sol

Status: Enrolling

Conditions: Pulmonary Arterial Hypertension

Treatments: Drug: No intervention - Observational study

Study type: Observational

Funder types: Other

Identifiers

NCT05600218

0991-N-21

Details and patient eligibility

About

This is an observational, ambrispective study of patients in real world clinical practice, who has pulmonary arterial hypertension in whom a prostacyclin IP receptor agonist (Selexipag) is initiated between 2017 and 2021.

The aim of this study answer the following questions:

• Changes in the mortality risk profile of these patients after treatment administration.
• Baseline characteristics of patients initiating Selexipag.
• Parameters used for risk stratification prior to treatment escalation.
• Events during follow-up.

No comparison group available

Enrollment: 60 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• They agree to participate in the study by signing an informed consent form

Exclusion criteria

• Decline to participate in the study
• Patients living 6 months or less in the reference health area
• Patients with active malignant tumors

Trial design

60 participants in 1 patient group

Cohort 1

Description:

Patients with pulmonary arterial hypertension on treatment with prostacyclin IP receptor agonists because they are at intermediate risk of mortality at one year

Treatment:

Drug: No intervention - Observational study